Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
Key Points
Key Points
- This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
- The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
- This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.
Treatment
Treatmen...
...ial Treatment
...ion 1.0(Updated) Docetaxel, abirater...
...PRIVATION THERAPY (ADT) PLUS DOCETAXEL...
...on 1.1(Updated) For patients with metasta...
...mendation 1.11(New) For patients with de n...
....15(New) For patients with de novo metas...
...ion 1.16(New) The recommended regimen for p...
...mmendation 1.2(Updated) For patients with...
...on 1.3(Updated) For patients with metastat...
...DT PLUS ABIRAT...
...ation 1.4For patients with high-risk de novo meta...
...mendation 1.5For patients with low-risk de novo me...
...tion 1.6The recommended regimen for pa...
...LUS ENZALUTAMIDE...
...commendation 1.7(Updated) ADT plus enzalut...
...n 1.8(Updated) The recommended regimen...
...PLUS APALUTAMIDE
Recommendation 1.9ADT plus apalutamide s...
...endation 1.95(Updated) The recomme...
...ombination Therapies...
...n 2.1ADT plus abiraterone and prednisolone shou...
...ecommendation 2.2In resource-constrained...
...drogen Deprivation...
Recommendation 3.1Early (immediate) ADT...
...ntermittent Androgen Deprivation
...ecommendation 4.1Intermittent therapy may...
.... Initial Management of Noncastrate Me...